

Ching-Lung Lai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5232674/publications.pdf>

Version: 2024-02-01

374
papers

36,322
citations

3874

91
h-index

4305

179
g-index

380
all docs

380
docs citations

380
times ranked

20247
citing authors

#	ARTICLE	IF	CITATIONS
1	Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. <i>Hepatology International</i> , 2016, 10, 1-98.	1.9	1,908
2	A One-Year Trial of Lamivudine for Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 1998, 339, 61-68.	13.9	1,773
3	Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2006, 354, 1011-1020.	13.9	1,118
4	Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. <i>New England Journal of Medicine</i> , 2015, 373, 2599-2607.	13.9	945
5	Viral hepatitis B. <i>Lancet, The</i> , 2003, 362, 2089-2094.	6.3	929
6	Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. <i>Hepatology</i> , 2010, 52, 886-893.	3.6	840
7	Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2007, 357, 2576-2588.	13.9	735
8	Long-term safety of lamivudine treatment in patients with chronic hepatitis B. <i>Gastroenterology</i> , 2003, 125, 1714-1722.	0.6	724
9	Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2003, 36, 687-696.	2.9	604
10	Lansoprazole for the Prevention of Recurrences of Ulcer Complications from Long-Term Low-Dose Aspirin Use. <i>New England Journal of Medicine</i> , 2002, 346, 2033-2038.	13.9	578
11	Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. <i>Hepatology</i> , 2001, 33, 1527-1532.	3.6	565
12	Adult-to-Adult Living Donor Liver Transplantation Using Extended Right Lobe Grafts. <i>Annals of Surgery</i> , 1997, 226, 261-270.	2.1	523
13	Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. <i>Journal of Hepatology</i> , 2009, 50, 80-88.	1.8	517
14	Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. <i>Hepatology</i> , 2010, 51, 422-430.	3.6	515
15	Hepatitis B virus infection. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18035.	18.1	490
16	Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. <i>Hepatology</i> , 2000, 31, 330-335.	3.6	408
17	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	1.8	401
18	Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region. <i>Gut and Liver</i> , 2016, 10, 332-9.	1.4	399

#	ARTICLE	IF	CITATIONS
19	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2005, 129, 528-536.	0.6	380
20	HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2008, 135, 1192-1199.	0.6	370
21	Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. <i>Cancer</i> , 1988, 62, 479-483.	2.0	356
22	Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. <i>Hepatology</i> , 2001, 34, 785-791.	3.6	354
23	SARS-associated viral hepatitis caused by a novel coronavirus: Report of three cases. <i>Hepatology</i> , 2004, 39, 302-310.	3.6	352
24	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	343
25	A 1-Year Trial of Telbivudine, Lamivudine, and the Combination in Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2005, 129, 528-536.	0.6	338
26	Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. <i>Gastroenterology</i> , 1987, 92, 1839-1843.	0.6	320
27	Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. <i>Gut</i> , 2005, 54, 1610-1614.	6.1	317
28	Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. <i>Gastroenterology</i> , 2002, 123, 1831-1838.	0.6	286
29	Hepatitis B Reactivation in Patients With Previous Hepatitis B Virus Exposure Undergoing Rituximab-Containing Chemotherapy for Lymphoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3736-3743.	0.8	283
30	Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. <i>Hepatology</i> , 2002, 36, 186-194.	3.6	274
31	Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. <i>Journal of Hepatology</i> , 1990, 10, 29-34.	1.8	245
32	A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. <i>Gastroenterology</i> , 1992, 102, 2091-2097.	0.6	241
33	Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results. <i>Liver Transplantation</i> , 2007, 13, 349-360.	1.3	239
34	Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. <i>Hepatology</i> , 2000, 31, 201-206.	3.6	230
35	Long-Term Lamivudine Therapy Reduces the Risk of Long-Term Complications of Chronic Hepatitis B Infection even in Patients without Advanced Disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-1304.	0.6	230
36	Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1276-1282.	1.4	227

#	ARTICLE	IF	CITATIONS
37	A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. <i>Cancer</i> , 2002, 94, 1747-1752.	2.0	222
38	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. <i>Hepatology</i> , 2004, 39, 1694-1701.	3.6	222
39	Recombinant interferon- β in inoperable hepatocellular carcinoma: A randomized controlled trial. <i>Hepatology</i> , 1993, 17, 389-394.	3.6	220
40	Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities. <i>Antiviral Research</i> , 2015, 121, 47-58.	1.9	216
41	Long-term follow-up of interferon alfa treatment in chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. <i>Hepatology</i> , 2001, 34, 139-145.	3.6	207
42	Natural history of hepatitis-related hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2008, 14, 1652.	1.4	203
43	Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. <i>Hepatology</i> , 2003, 38, 1419-1427.	3.6	190
44	Entecavir Monotherapy Is Effective in Suppressing Hepatitis B Virus After Liver Transplantation. <i>Gastroenterology</i> , 2011, 141, 1212-1219.	0.6	190
45	A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive chinese children. <i>Hepatology</i> , 1988, 8, 1130-1133.	3.6	189
46	Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. <i>Gut</i> , 2015, 64, 667-672.	6.1	185
47	β -fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma. <i>Hepatology</i> , 1989, 9, 110-115.	3.6	183
48	Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. <i>Hepatology</i> , 2013, 57, 399-408.	3.6	183
49	Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis with Telbivudine or Adefovir. <i>Annals of Internal Medicine</i> , 2007, 147, 745.	2.0	175
50	Recurrence of Hepatitis B-Related Hepatocellular Carcinoma Is Associated With High Viral Load at the Time of Resection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1663-1673.	0.2	175
51	LONG-TERM FOLLOW-UP IN A RANDOMISED CONTROLLED TRIAL OF RECOMBINANT β -INTERFERON IN CHINESE PATIENTS WITH CHRONIC HEPATITIS B INFECTION. <i>Lancet</i> , The, 1988, 332, 298-302.	6.3	169
52	Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 2715-2725.	1.3	168
53	PLACEBO-CONTROLLED TRIAL OF RECOMBINANT β -INTERFERON IN CHINESE HBsAg-CARRIER CHILDREN. <i>Lancet</i> , The, 1987, 330, 877-880.	6.3	164
54	The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. <i>Annals of Internal Medicine</i> , 2007, 147, 58.	2.0	163

#	ARTICLE	IF	CITATIONS
55	Review article: hepatitis B core-related antigen (<sc>HB</sc>crAg): an emerging marker for chronic hepatitis B virus infection. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 43-54.	1.9	161
56	A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. <i>Hepatology</i> , 2002, 36, 687-691.	3.6	157
57	Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. <i>Gut</i> , 2007, 57, 98-102.	6.1	154
58	MINIMUM GRAFT VOLUME FOR SUCCESSFUL ADULT-TO-ADULT LIVING DONOR LIVER TRANSPLANTATION FOR FULMINANT HEPATIC FAILURE. <i>Transplantation</i> , 1996, 62, 696-698.	0.5	151
59	Prevalence of isolated antibody to hepatitis B core antigen in an area endemic for hepatitis B virus infection: Implications in hepatitis B vaccination programs. <i>Hepatology</i> , 1988, 8, 766-770.	3.6	147
60	Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. <i>Hepatology</i> , 2003, 37, 562-567.	3.6	146
61	Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety. <i>American Journal of Gastroenterology</i> , 2011, 106, 1264-1271.	0.2	145
62	Treatment of chronic hepatitis B: Evolution over two decades. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 138-143.	1.4	143
63	Hepatitis B Virus Core-Related Antigens as Markers for Monitoring Chronic Hepatitis B Infection. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3942-3947.	1.8	139
64	Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. <i>Hepatology</i> , 2011, 54, 829-836.	3.6	135
65	Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA. <i>Liver International</i> , 2017, 37, 995-1001.	1.9	132
66	HEPATITIS B VIRUS INFECTION IN CHINESE FAMILIES IN HONGKONG. <i>American Journal of Epidemiology</i> , 1987, 126, 492-499.	1.6	128
67	Expression of c-Myc, c-Fos, and c-Jun in hepatocellular carcinoma. <i>Cancer</i> , 2001, 91, 106-112.	2.0	127
68	Clinicopathological and prognostic significance of serum and tissue <sc>Dickkopf1</sc> levels in human hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 1494-1504.	1.9	127
69	Molecular Characterization of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus in Paid Blood Donors and Injection Drug Users in China. <i>Journal of Virology</i> , 2004, 78, 13591-13599.	1.5	126
70	Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , 2017, 66, 275-281.	1.8	126
71	Specific mutations in enhancer II/core promoter of hepatitis B virus subgenotypes C1/C2 increase the risk of hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 646-653.	1.8	124
72	Hepatitis B and C virus-related carcinogenesis. <i>Clinical Microbiology and Infection</i> , 2009, 15, 964-970.	2.8	123

#	ARTICLE	IF	CITATIONS
73	Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis. <i>Annals of Surgery</i> , 2001, 233, 276-281.	2.1	122
74	Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1004-1010.e1.	2.4	122
75	Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. <i>Hepatology</i> , 2004, 40, 727-737.	3.6	119
76	Serological markers of liver cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2005, 19, 91-99.	1.0	118
77	Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. <i>Antiviral Research</i> , 2015, 121, 97-108.	1.9	116
78	A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. <i>Gut</i> , 2003, 52, 416-419.	6.1	113
79	Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. <i>Hepatology</i> , 2007, 46, 1695-1703.	3.6	111
80	Long COVID-19 Syndrome: A Comprehensive Review of Its Effect on Various Organ Systems and Recommendation on Rehabilitation Plans. <i>Biomedicines</i> , 2021, 9, 966.	1.4	111
81	Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1173-1180.	2.8	110
82	Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B. <i>American Journal of Gastroenterology</i> , 2013, 108, 942-948.	0.2	108
83	Chronic Hepatitis B "New Goals, New Treatment. <i>New England Journal of Medicine</i> , 2008, 359, 2488-2491.	13.9	107
84	Molecular Tracing of the Global Hepatitis C Virus Epidemic Predicts Regional Patterns of Hepatocellular Carcinoma Mortality. <i>Gastroenterology</i> , 2006, 130, 703-714.	0.6	106
85	Traditional Chinese medicine causing hepatotoxicity in patients with chronic hepatitis B infection: a 1-year prospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 1179-1186.	1.9	103
86	PIN1 overexpression and β -catenin gene mutations are distinct oncogenic events in human hepatocellular carcinoma. <i>Oncogene</i> , 2004, 23, 4182-4186.	2.6	101
87	COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. <i>Pharmaceuticals</i> , 2021, 14, 406.	1.7	101
88	Telbivudine Improves Renal Function in Patients With Chronic Hepatitis B. <i>Gastroenterology</i> , 2014, 146, 138-146.e5.	0.6	99
89	A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 2004, 40, 719-726.	3.6	96
90	Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: The case for continuous antiviral therapy. <i>Journal of Hepatology</i> , 2009, 50, 289-295.	1.8	96

#	ARTICLE	IF	CITATIONS
91	18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 941-945.	2.4	94
92	Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e125.	1.3	93
93	One-Year Entecavir or Lamivudine Therapy Results in Reduction of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA Levels. <i>Antiviral Therapy</i> , 2006, 11, 909-916.	0.6	93
94	Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. <i>Carcinogenesis</i> , 2004, 25, 1593-1598.	1.3	92
95	Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. <i>Hepatology</i> , 2017, 66, 1036-1044.	3.6	89
96	Treatment of chronic hepatitis B. <i>Lancet Infectious Diseases</i> , The, 2001, 1, 232-241.	4.6	88
97	Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. <i>Hepatology</i> , 2013, 58, 923-931.	3.6	88
98	Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 575-583.e2.	2.4	86
99	Mannose-binding lectin in chronic hepatitis B virus infection. <i>Hepatology</i> , 2005, 42, 1037-1045.	3.6	85
100	Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2006, 45, 553-559.	1.8	84
101	RNA Interference Therapy With ARC520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection. <i>Hepatology</i> , 2020, 72, 19-31.	3.6	84
102	Transmissibility of Hepatitis B Virus (HBV) Infection through Blood Transfusion from Blood Donors with Occult HBV Infection. <i>Clinical Infectious Diseases</i> , 2011, 52, 624-632.	2.9	83
103	Interferon antibodies may negate the antiviral effects of recombinant α -interferon treatment in patients with chronic hepatitis B virus infection. <i>Hepatology</i> , 1990, 12, 1266-1270.	3.6	82
104	Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2011, 203, 646-654.	1.9	82
105	A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2012, 56, 812-819.	3.6	82
106	Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. <i>Hepatology</i> , 2017, 65, 1451-1461.	3.6	81
107	Chronic Hepatitis C Virus Genotype 6 Infection: Response to Pegylated Interferon and Ribavirin. <i>Journal of Infectious Diseases</i> , 2008, 198, 808-812.	1.9	80
108	Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. <i>Antiviral Therapy</i> , 2007, 12, 1295-303.	0.6	78

#	ARTICLE	IF	CITATIONS
109	Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. <i>Liver International</i> , 2008, 28, 1408-1416.	1.9	77
110	Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 428-434.	1.4	77
111	Relationship between the Development of Precore and Core Promoter Mutations and Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B Virus. <i>Journal of Infectious Diseases</i> , 2002, 186, 1335-1338.	1.9	76
112	The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2005, 12, 373-379.	1.0	76
113	Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection. <i>Hepatology</i> , 1999, 29, 1248-1251.	3.6	75
114	Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 573-583.	1.9	75
115	Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: Final report. <i>Vaccine</i> , 2008, 26, 6587-6591.	1.7	74
116	T1653 Mutation in the Box a Increases the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Virus Genotype C Infection. <i>Clinical Infectious Diseases</i> , 2006, 42, 1-7.	2.9	73
117	Executive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management. <i>Kidney International</i> , 2018, 94, 663-673.	2.6	72
118	High Hepatitis B Surface Antigen Levels Predict Insignificant Fibrosis in Hepatitis B e Antigen Positive Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e43087.	1.1	71
119	Mutational analysis of 65 Wilson disease patients in Hong Kong Chinese: Identification of 17 novel mutations and its genetic heterogeneity. <i>Journal of Human Genetics</i> , 2008, 53, 55-63.	1.1	69
120	Safety, Tolerability, and Pharmacokinetics of ARCA520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 350-362.	0.8	69
121	APPLICABILITY OF LIVING DONOR LIVER TRANSPLANTATION TO HIGH-URGENCY PATIENTS. <i>Transplantation</i> , 1999, 67, 73-77.	0.5	69
122	A New Model Using Routinely Available Clinical Parameters to Predict Significant Liver Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2011, 6, e23077.	1.1	69
123	Does the Addition of Endoscopic Sphincterotomy to Stent Insertion Improve Drainage of the Bile Duct in Acute Suppurative Cholangitis?. <i>Gastrointestinal Endoscopy</i> , 2003, 58, 500-504.	0.5	68
124	The Duration of Lamivudine Therapy for Chronic Hepatitis B: Cessation vs. Continuation of Treatment After HBeAg Seroconversion. <i>American Journal of Gastroenterology</i> , 2009, 104, 1940-1946.	0.2	68
125	Retained common bile duct stones: a comparison between biliary stenting and complete clearance of stones by electrohydraulic lithotripsy. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 289-296.	1.9	67
126	Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. <i>Gut</i> , 2014, 63, 996-1004.	6.1	67

#	ARTICLE	IF	CITATIONS
127	High prevalence of non-alcoholic fatty liver disease in the Chinese – results from the Hong Kong liver health census. <i>Liver International</i> , 2015, 35, 542-549.	1.9	67
128	Hepatitis B Virus Genotypes B and C Do Not Affect the Antiviral Response to Lamivudine. <i>Antiviral Therapy</i> , 2003, 8, 531-534.	0.6	67
129	Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children. <i>Hepatology</i> , 1999, 29, 924-927.	3.6	66
130	Development of antibody to hepatitis B surface antigen after liver transplantation for chronic hepatitis B. <i>Hepatology</i> , 2003, 37, 36-43.	3.6	65
131	Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. <i>Gut</i> , 2010, 59, 1389-1393.	6.1	65
132	A Large Population Histology Study Showing the Lack of Association between ALT Elevation and Significant Fibrosis in Chronic Hepatitis B. <i>PLoS ONE</i> , 2012, 7, e32622.	1.1	65
133	Necrotizing enterocolitis in neonates with symptomatic congenital heart disease. <i>Journal of Pediatrics</i> , 1988, 113, 1044-1049.	0.9	64
134	Does withholding aspirin for one week reduce the risk of post-sphincterotomy bleeding?. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 929-936.	1.9	64
135	Epidemiological study of hepatitis B virus genotypes, core promoter and precore mutations of chronic hepatitis B infection in Hong Kong. <i>Journal of Hepatology</i> , 2004, 41, 119-125.	1.8	64
136	Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1766-1773.	0.2	62
137	Acute-on-chronic liver failure in chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 662-669.	1.4	62
138	Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. <i>Journal of Viral Hepatitis</i> , 2017, 24, 654-661.	1.0	62
139	Prostaglandin E1 (Misoprostol) overcomes the adverse effect of chronic cigarette smoking on duodenal ulcer healing. <i>Digestive Diseases and Sciences</i> , 1986, 31, 68S-74S.	1.1	59
140	Interferon and Ribavirin Therapy for Chronic Hepatitis C Virus Genotype 6: A Comparison with Genotype 1. <i>Journal of Infectious Diseases</i> , 2003, 187, 1071-1074.	1.9	58
141	Live-donor liver transplantation for acute-on-chronic hepatitis B liver failure. <i>Transplantation</i> , 2003, 76, 1174-1179.	0.5	58
142	HLA-DP and IL28B Polymorphisms: Influence of Host Genome on Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2013, 56, 1695-1703.	2.9	58
143	Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1028-1034.	1.4	58
144	Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 1788-1795.	0.2	58

#	ARTICLE	IF	CITATIONS
145	Natural history of chronic hepatitis B virus infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, E20-E24.	1.4	57
146	Two subtypes (subgenotypes) of hepatitis B virus genotype C: A novel subtyping assay based on restriction fragment length polymorphism. <i>Hepatology Research</i> , 2005, 33, 216-24.	1.8	56
147	Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2011, 6, e28798.	1.1	56
148	Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses. <i>Hepatology</i> , 1993, 18, 763-767.	3.6	55
149	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003, 39, 850-855.	1.8	55
150	Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. <i>Hepatology</i> , 1995, 22, 25-29.	3.6	54
151	Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome. <i>Antiviral Research</i> , 2017, 144, 1-7.	1.9	54
152	Acute cholangitis-predictive factors for emergency ERCP. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1633-1637.	1.9	52
153	Correlation of Liver Stiffness and Histological Features in Healthy Persons and in Patients With Occult Hepatitis B, Chronic Active Hepatitis B, or Hepatitis B Cirrhosis. <i>American Journal of Gastroenterology</i> , 2010, 105, 1116-1122.	0.2	52
154	Mild-to-Moderate Elevation of Alanine Aminotransferase Increases Liver Stiffness Measurement by Transient Elastography in Patients With Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2011, 106, 492-496.	0.2	52
155	Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. <i>Journal of Hepatology</i> , 2013, 59, 709-716.	1.8	52
156	Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. <i>Oncotarget</i> , 2015, 6, 34941-34952.	0.8	52
157	Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2004, 99, 2032-2037.	0.2	51
158	Persistence of <i>Campylobacter pyloridis</i> despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. <i>Digestive Diseases and Sciences</i> , 1987, 32, 1255-1260.	1.1	50
159	Epidemiology and Natural History of Primary Biliary Cholangitis in the Chinese: A Territory-Based Study in Hong Kong between 2000 and 2015. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e116.	1.3	48
160	Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B surface antigen seroclearance. <i>Hepatology</i> , 2018, 68, 462-472.	3.6	48
161	Mirtazapine-Induced Hepatotoxicity. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 270-271.	1.1	47
162	Prevalence of Fibrosis and Cirrhosis in Chronic Hepatitis B: Implications for Treatment and Management. <i>American Journal of Gastroenterology</i> , 2008, 103, 1421-1426.	0.2	47

#	ARTICLE	IF	CITATIONS
163	Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. <i>Journal of Viral Hepatitis</i> , 2011, 18, e200-5.	1.0	47
164	Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 449-456.	2.4	47
165	Characterization of interleukin-1 β in <i>Helicobacter pylori</i> -induced gastric inflammation and DNA methylation in interleukin-1 receptor type 1 knockout (IL-1R1 $^{-/-}$) mice. <i>European Journal of Cancer</i> , 2013, 49, 2760-2770.	1.3	46
166	Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: Results from a multicentre study. <i>Journal of Hepatology</i> , 2015, 62, 526-532.	1.8	46
167	Profound suppression of hepatitis B virus replication with lamivudine. <i>Journal of Medical Virology</i> , 2000, 61, 367-373.	2.5	45
168	Screening for hepatocellular carcinoma: survival benefit and cost-effectiveness. <i>Annals of Oncology</i> , 2003, 14, 1463-1467.	0.6	45
169	Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. <i>Hepatology</i> , 2010, 51, 1185-1189.	3.6	45
170	Significance of isolated anti-HBc seropositivity by ELISA: Implications and the role of radioimmunoassay. <i>Journal of Medical Virology</i> , 1992, 36, 180-183.	2.5	44
171	Transcatheter Arterial Chemoembolization in Inoperable Hepatocellular Carcinoma: Four-year Follow-up. <i>Journal of Vascular and Interventional Radiology</i> , 1996, 7, 419-425.	0.2	44
172	Prognostic Factors in Severe Exacerbation of Chronic Hepatitis B. <i>Clinical Infectious Diseases</i> , 2003, 36, 979-984.	2.9	44
173	Overestimation of the prevalence of antibody to hepatitis C virus in retrospective studies on stored sera. <i>Hepatology</i> , 1991, 14, 756-762.	3.6	43
174	Hepatocellular carcinoma in chinese males and females. Possible causes for the male predominance. <i>Cancer</i> , 1987, 60, 1107-1110.	2.0	42
175	Transarterial Chemoembolization for Inoperable, Early Stage Hepatocellular Carcinoma in Patients With Child-Pugh Grade A and B: Results of A Comparative Study in 96 Chinese Patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 1181-1185.	0.2	42
176	Hepatitis B Virus with Primary Resistance to Adefovir. <i>New England Journal of Medicine</i> , 2006, 355, 322-323.	13.9	42
177	Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg-negative chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2011, 18, 738-744.	1.0	42
178	Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, 286-294.	1.1	42
179	Role of HLA-DP Polymorphisms on Chronicity and Disease Activity of Hepatitis B Infection in Southern Chinese. <i>PLoS ONE</i> , 2013, 8, e66920.	1.1	42
180	Pharmacokinetics of Telbivudine following Oral Administration of Escalating Single and Multiple Doses in Patients with Chronic Hepatitis B Virus Infection: Pharmacodynamic Implications. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 874-879.	1.4	40

#	ARTICLE	IF	CITATIONS
181	Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. <i>Journal of Viral Hepatitis</i> , 2019, 26, 818-827.	1.0	40
182	Adefovir Dipivoxil Monotherapy and Combination Therapy with Lamivudine for the Treatment of Chronic Hepatitis B in an Asian Population. <i>Antiviral Therapy</i> , 2007, 12, 41-46.	0.6	40
183	A Randomized Placebo-Controlled, Dose-Finding Study of Oral Lb80380 in Hbeag-Positive Patients with Chronic Hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 977-984.	0.6	40
184	Effect of Lamivudine Therapy on the Serum Covalently Closed-Circular (ccc) DNA of Chronic Hepatitis B Infection. <i>American Journal of Gastroenterology</i> , 2005, 100, 1099-1103.	0.2	39
185	Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. <i>Hepatology</i> , 2010, 51, 767-776.	3.6	39
186	Epidemiology and natural history of Wilson's disease in the Chinese: A territory-based study in Hong Kong between 2000 and 2016. <i>World Journal of Gastroenterology</i> , 2017, 23, 7716-7726.	1.4	39
187	Factors influencing healing of duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1985, 30, 45-51.	1.1	38
188	Prophylaxis and treatment of recurrent hepatitis B after liver transplantation. <i>Transplantation</i> , 2003, 75, S41-S44.	0.5	38
189	Psychometrics of the chronic liver disease questionnaire for Southern Chinese patients with chronic hepatitis B virus infection. <i>World Journal of Gastroenterology</i> , 2009, 15, 3288.	1.4	38
190	Defining Normal Liver Stiffness Range in a Normal Healthy Chinese Population without Liver Disease. <i>PLoS ONE</i> , 2013, 8, e85067.	1.1	38
191	Current seroepidemiology of hepatitis A in Hong Kong. <i>Journal of Medical Virology</i> , 1991, 34, 191-193.	2.5	37
192	A randomised controlled trial of endoscopic sphincterotomy in acute cholangitis without common bile duct stones. <i>Gut</i> , 2002, 51, 245-247.	6.1	37
193	Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation. <i>Clinical Infectious Diseases</i> , 2003, 37, 593-597.	2.9	37
194	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. <i>Cancer Letters</i> , 2017, 403, 330-338.	3.2	37
195	Difference in T helper responses during hepatitis flares in hepatitis B e antigen (HBeAg)-positive patients with genotypes B and C: implication for early HBeAg seroconversion. <i>Journal of Viral Hepatitis</i> , 2007, 14, 269-275.	1.0	36
196	Prevention and management of drug resistance for antihepatitis B treatment. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 256-264.	4.6	36
197	Prevention of hepatocellular carcinoma in chronic viral hepatitis B and C infection. <i>World Journal of Gastroenterology</i> , 2013, 19, 8887.	1.4	36
198	Real-Time PCR Assay Using Molecular Beacon for Quantitation of Hepatitis B Virus DNA. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3438-3440.	1.8	35

#	ARTICLE	IF	CITATIONS
199	Natural history of chronic hepatitis C: Genotype 1 versus genotype 6. <i>Journal of Hepatology</i> , 2010, 53, 444-448.	1.8	35
200	Chronic Antral Gastritis in Duodenal Ulcer. <i>Gastroenterology</i> , 1986, 91, 1095-1101.	0.6	34
201	Longitudinal Study of Hepatitis Activity and Viral Replication before and after HBeAg Seroconversion in Chronic Hepatitis B Patients Infected with Genotypes B and C. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5036-5040.	1.8	34
202	Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a caseâ€“control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 377-382.	1.9	34
203	Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay. <i>Hepatology International</i> , 2013, 7, 98-105.	1.9	34
204	Hepatitis B core protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2017, 21, 1153-1159.	1.5	34
205	Response to Combined Interferon and Ribavirin Is Better in Patients Infected with Hepatitis C Virus Genotype 6 than Genotype 1 in Hong Kong. <i>Intervirology</i> , 2006, 49, 96-98.	1.2	33
206	Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome. <i>Journal of Hepatology</i> , 2011, 55, 522-528.	1.8	33
207	Bodyâ€“mass index is associated with fibrosis regression during longâ€“term nucleoside analogue therapy in chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 1071-1079.	1.9	33
208	Ketamine-Induced Cholangiopathy: A Case Report. <i>American Journal of Gastroenterology</i> , 2011, 106, 1004-1005.	0.2	32
209	A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong. <i>Journal of Infectious Diseases</i> , 2019, 219, 1924-1933.	1.9	32
210	Nucleic Acid-Based Cross-Linking Assay for Detection and Quantification of Hepatitis B Virus DNA. <i>Journal of Clinical Microbiology</i> , 1999, 37, 161-164.	1.8	32
211	One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. <i>Antiviral Therapy</i> , 2006, 11, 909-16.	0.6	32
212	Low Molecular Weight Heparin-Induced Liver Toxicity. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 691-694.	1.0	31
213	Hbsag seroclearance in the natural history of chronic hepatitis b infection. <i>Current Hepatitis Reports</i> , 2006, 5, 23-26.	0.3	31
214	Mechanism of Entecavir Resistance of Hepatitis B Virus with Viral Breakthrough as Determined by Long-Term Clinical Assessment and Molecular Docking Simulation. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 882-889.	1.4	31
215	Real-time quantification of hepatitis B virus core-promoter and pre-core mutants during hepatitis E antigen seroconversion. <i>Journal of Hepatology</i> , 2004, 40, 1008-1017.	1.8	30
216	Use of Liver Stiffness Measurement for Liver Resection Surgery: Correlation with Indocyanine Green Clearance Testing and Post-Operative Outcome. <i>PLoS ONE</i> , 2013, 8, e72306.	1.1	30

#	ARTICLE	IF	CITATIONS
217	Effects of nucleoside analogue prescription for hepatitis B on the incidence of liver cancer in Hong Kong: a territory-wide ecological study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 501-509.	1.9	30
218	An oligonucleotide probe for the detection of hepatitis B virus DNA in serum. <i>Journal of Virological Methods</i> , 1987, 15, 139-149.	1.0	29
219	Reduction of liver stiffness following resolution of acute flares of chronic hepatitis B. <i>Hepatology International</i> , 2010, 4, 716-722.	1.9	29
220	Profiles of HBV DNA in a large population of Chinese patients with chronic hepatitis B: Implications for antiviral therapy. <i>Journal of Hepatology</i> , 2011, 54, 195-200.	1.8	29
221	Rebound of HBV DNA after cessation of nucleos(tide) analogues in chronic hepatitis B patients with undetectable covalently closed circular DNA. <i>JHEP Reports</i> , 2020, 2, 100112.	2.6	29
222	<i>Wisteria floribunda</i> agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment. <i>Oncotarget</i> , 2017, 8, 47507-47517.	0.8	29
223	Factors determining the development of hepatocellular carcinoma in hepatitis b surface antigen carriers. A comparison between families with clusters and solitary cases. <i>Cancer</i> , 1988, 61, 1287-1291.	2.0	28
224	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. <i>Liver Transplantation</i> , 2004, 10, 557-563.	1.3	28
225	Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability. <i>Journal of Gastroenterology</i> , 2016, 51, 487-495.	2.3	28
226	Evolution of Primary and Compensatory Lamivudine Resistance Mutations in Chronic Hepatitis B Virus-Infected Patients during Long-Term Lamivudine Treatment, Assessed by a Line Probe Assay. <i>Journal of Clinical Microbiology</i> , 2007, 45, 3935-3941.	1.8	27
227	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
228	Interferon therapy of chronic hepatitis B virus infection in Chinese. <i>Journal of Hepatology</i> , 1986, 3, S209-S215.	1.8	26
229	Acute pancreatitis complicating acute exacerbation of chronic hepatitis B infection carries a poor prognosis. <i>Journal of Viral Hepatitis</i> , 2001, 8, 459-464.	1.0	26
230	Interleukin-1 β increases the risk of gastric cancer through induction of aberrant DNA methylation in a mouse model. <i>Oncology Letters</i> , 2016, 11, 2919-2924.	0.8	26
231	Sofosbuvir plus ribavirin for the treatment of patients with chronic genotype 1 or 6 hepatitis C virus infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 96-101.	1.9	26
232	Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. <i>Clinical and Translational Gastroenterology</i> , 2018, 9, e163.	1.3	26
233	CLINICOPATHOLOGIC FEATURES OF HEPATITIS C VIRUS INFECTION IN RENAL ALLOGRAFT RECIPIENTS. <i>Transplantation</i> , 1994, 58, 996-1000.	0.5	25
234	Hepatic Expression of Hepatitis B Virus Genome in Chronic Hepatitis B Virus Infection. <i>American Journal of Clinical Pathology</i> , 1996, 105, 87-95.	0.4	25

#	ARTICLE	IF	CITATIONS
235	Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma. <i>Liver International</i> , 1999, 19, 444-451.	1.9	25
236	Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 841-849.	1.9	25
237	Safety evaluation of telbivudine. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 821-829.	1.0	25
238	Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety. <i>Current Hepatitis Reports</i> , 2011, 10, 235-243.	0.3	25
239	Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment. <i>Gut</i> , 2022, 71, 789-797.	6.1	25
240	Hepatitis B Genotypes in Chronic Hepatitis B and Lamivudine Therapy. <i>Intervirolgy</i> , 2003, 46, 373-376.	1.2	24
241	Combination Therapy for Chronic Hepatitis B: Simultaneous or Sequential?. <i>American Journal of Gastroenterology</i> , 2007, 102, 105-106.	0.2	24
242	Etiologies of chronic liver diseases in Hong Kong. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 659-664.	0.8	24
243	Role of γ 2B8B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection. <i>Journal of Viral Hepatitis</i> , 2013, 20, 470-477.	1.0	24
244	Hepatic necroinflammation and fibrosis in patients with genotypes Ba and C, core-promoter and precore mutations. <i>Journal of Viral Hepatitis</i> , 2005, 12, 513-518.	1.0	23
245	New paradigms for the treatment of chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1182-1192.	1.4	23
246	Prognostic Factors for Transplant-Free Survival and Validation of Prognostic Models in Chinese Patients with Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid. <i>Clinical and Translational Gastroenterology</i> , 2017, 8, e100.	1.3	23
247	HBsAg Seroclearance in Chinese Patients Receiving Lamivudine Therapy for Chronic Hepatitis B Virus Infection. <i>Journal of Clinical Microbiology</i> , 2004, 42, 4882-4884.	1.8	22
248	LB80380: a promising new drug for the treatment of chronic hepatitis B. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1581-1588.	1.9	22
249	DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 383-392.	1.0	22
250	Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1473-1480.	1.0	22
251	Detection of Intrahepatic Hepatitis B Virus DNA and Correlation with Hepatic Necroinflammation and Fibrosis. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3920-3924.	1.8	21
252	Adefovir dipivoxil in chronic hepatitis B infection. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 2361-2367.	0.9	21

#	ARTICLE	IF	CITATIONS
253	Pharmacokinetics of LB80331 and LB80317 following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1779-1785.	1.4	21
254	Outcomes including liver histology after liver transplantation for chronic hepatitis B using oral antiviral therapy alone. <i>Liver Transplantation</i> , 2015, 21, 1504-1510.	1.3	21
255	Significance of Viral Load, Core Promoter/Precore Mutations and Specific Sequences of Polymerase Gene in Hbv-Infected Patients on 3-Year Lamivudine Treatment. <i>Antiviral Therapy</i> , 2006, 11, 779-786.	0.6	21
256	The hepatitis C virus genome: a guide to its conserved sequences and candidate epitopes. <i>Virus Research</i> , 1993, 30, 27-41.	1.1	20
257	Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. <i>Annals of Internal Medicine</i> , 2019, 171, 496.	2.0	20
258	Absence of transmission of hepatitis B by fiberoptic upper gastrointestinal endoscopy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 175-180.	1.4	19
259	Comparison of the efficacy of lamivudine and famciclovir in Asian patients with chronic hepatitis B: Results of 24 weeks of therapy. <i>Journal of Medical Virology</i> , 2002, 67, 334-338.	2.5	19
260	Hepatitis B virus DNA and hepatitis B surface antigen levels in chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2010, 8, 717-726.	2.0	19
261	Hepatitis B Surface Antigen Seroclearance: Relationship to Hepatitis B e-Antigen Seroclearance and Hepatitis B e-Antigen-Negative Hepatitis. <i>American Journal of Gastroenterology</i> , 2014, 109, 1764-1770.	0.2	19
262	Risk Factors and Post-Resection Independent Predictive Score for the Recurrence of Hepatitis B-Related Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0148493.	1.1	19
263	Prevention and management of hepatitis B virus reactivation in cancer patients. <i>Hepatology International</i> , 2016, 10, 407-414.	1.9	19
264	Hepatotoxicity due to a formulation of <i>Ganoderma lucidum</i> (lingzhi). <i>Journal of Hepatology</i> , 2004, 41, 686-687.	1.8	18
265	Outcome of Lamivudine-Resistant Chronic Hepatitis B after up to 5 Years of Combination Therapy with Adefovir. <i>Antiviral Therapy</i> , 2012, 17, 1255-1262.	0.6	18
266	Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive, nucleoside-naïve patients treated with entecavir. <i>Antiviral Therapy</i> , 2013, 18, 691-698.	0.6	18
267	HBV X protein mutations affect HBV transcription and association of histone-modifying enzymes with covalently closed circular DNA. <i>Scientific Reports</i> , 2020, 10, 802.	1.6	18
268	Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and nonmalignant hepatitis B virus-related chronic liver diseases. <i>Hepatology</i> , 1991, 13, 834-837.	3.6	17
269	The Role of Steatosis in HBsAg Seroclearance for Patients with Chronic Hepatitis B Infection: Fact or Fiction?. <i>Digestive Diseases and Sciences</i> , 2013, 58, 20-22.	1.1	17
270	The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187.	1.9	17

#	ARTICLE	IF	CITATIONS
271	Comparison of the COBAS TaqMan [®] , [†] HBV test with the COBAS Amplicor monitor [®] , [‡] test for measurement of hepatitis B virus DNA in serum. <i>Journal of Medical Virology</i> , 2005, 77, 486-490.	2.5	16
272	Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1230-1233.	1.4	16
273	A large real-world cohort study examining the effects of long-term entecavir on hepatocellular carcinoma and HBsAg seroclearance. <i>Journal of Viral Hepatitis</i> , 2020, 27, 397-406.	1.0	16
274	Management of chronic hepatitis B in severe liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 16053.	1.4	16
275	A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. <i>Antiviral Therapy</i> , 2006, 11, 977-83.	0.6	16
276	Pathogenetic role of <i>Campylobacter pyloridis</i> in gastric ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1987, 2, 309-316.	1.4	15
277	Relationship Between Intrahepatic Expression of Hepatitis B Viral Antigens and Histology in Chinese Patients With Chronic Hepatitis B Virus Infection. <i>American Journal of Clinical Pathology</i> , 1993, 100, 648-653.	0.4	15
278	Intestinal tuberculosis mimicking fistulizing Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 137-139.	1.4	15
279	The Effects of IL-28B and ITPA Polymorphisms on Treatment of Hepatitis C Virus Genotype 6. <i>American Journal of Gastroenterology</i> , 2011, 106, 1007-1008.	0.2	15
280	Sequence Variations of Full-Length Hepatitis B Virus Genomes in Chinese Patients with HBsAg-Negative Hepatitis B Infection. <i>PLoS ONE</i> , 2014, 9, e99028.	1.1	15
281	Adefovir dipivoxil monotherapy and combination therapy with lamivudine for the treatment of chronic hepatitis B in an Asian population. <i>Antiviral Therapy</i> , 2007, 12, 41-6.	0.6	15
282	Synergism of chronic alcoholism and hepatitis B infection in liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1989, 4, 11-16.	1.4	14
283	Antiviral therapy for hepatitis B and C in Asians. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1999, 14, S19-S21.	1.4	14
284	Cholangiocarcinoma in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 337-341.	1.4	14
285	Long-Term Follow-Up Study of Chinese Patients with YMDD Mutations: Significance of Hepatitis B Virus Genotypes and Characteristics of Biochemical Flares. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3932-3936.	1.8	14
286	Outpatients undergoing therapeutic endoscopic retrograde cholangiopancreatography: Six-hour versus overnight observation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 1163-1168.	1.4	14
287	Hepatitis B virus genotypes: natural history and implications for treatment. <i>Expert Review of Gastroenterology and Hepatology</i> , 2007, 1, 321-328.	1.4	14
288	The use of transient elastography in the management of chronic hepatitis B. <i>Hepatology International</i> , 2011, 5, 868-875.	1.9	14

#	ARTICLE	IF	CITATIONS
289	High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 1047-1050.e1.	2.4	14
290	Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma. <i>Journal of Gastroenterology</i> , 2017, 52, 1064-1074.	2.3	14
291	2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference Report. <i>Kidney International Reports</i> , 2020, 5, 1129-1138.	0.4	14
292	Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients. <i>World Journal of Gastroenterology</i> , 2019, 25, 1398-1408.	1.4	14
293	Lamivudine prophylaxis in liver transplantation for hepatitis B in Asians. <i>Transplantation Proceedings</i> , 1999, 31, 535-536.	0.3	13
294	A pilot study of transcatheter arterial interferon embolization for patients with hepatocellular carcinoma. <i>Cancer</i> , 2003, 97, 2776-2782.	2.0	13
295	The Role of Cholecystectomy in Reducing Recurrent Gallstone Pancreatitis. <i>Endoscopy</i> , 2004, 36, 206-211.	1.0	13
296	A case-control study of response to lamivudine therapy for 2 years in Japanese and Chinese patients chronically infected with hepatitis B virus of genotypes Bj, Ba and C. <i>Hepatology Research</i> , 2006, 35, 127-134.	1.8	13
297	Evolutionary Changes of Hepatitis B Virus Pre-S Mutations Prior to Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0139478.	1.1	13
298	Reducing meal-stimulated acid secretion versus reducing nocturnal acid secretion for healing of duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1989, 34, 1494-1500.	1.1	12
299	Clinical Evaluation of the Digene Hybrid Capture II Test and the COBAS AMPLICOR Monitor Test for Determination of Hepatitis B Virus DNA Levels. <i>Journal of Clinical Microbiology</i> , 2004, 42, 3513-3517.	1.8	12
300	Precore and core promoter mutations at the time of HBeAg seroclearance in Chinese patients with chronic hepatitis B. <i>Journal of Infection</i> , 2007, 54, 497-503.	1.7	12
301	Mutational analysis for Wilson's disease. <i>Lancet, The</i> , 2009, 374, 662.	6.3	12
302	Profile of pre-S deletions in the natural history of chronic hepatitis B infection. <i>Journal of Medical Virology</i> , 2010, 82, 1843-1849.	2.5	12
303	Randomized trial of lamivudine versus entecavir in entecavir-treated patients with undetectable hepatitis B virus DNA: Outcome at 2 Years. <i>Hepatology</i> , 2011, 53, 1148-1153.	3.6	12
304	Application of Coamplification at Lower Denaturation Temperature-PCR Sequencing for Early Detection of Antiviral Drug Resistance Mutations of Hepatitis B Virus. <i>Journal of Clinical Microbiology</i> , 2014, 52, 3209-3215.	1.8	12
305	HBV research moves forward-receptors and reactivation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 70-72.	8.2	12
306	Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection. <i>Hepatology International</i> , 2019, 13, 148-156.	1.9	12

#	ARTICLE	IF	CITATIONS
307	Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1817-1823.	1.4	12
308	Case report of symptomatic porphyria cutanea tarda associated with histiocytic lymphoma. <i>Cancer</i> , 1984, 53, 573-576.	2.0	11
309	Systemic corticosteroid and reactivation of chronic hepatitis B. <i>Respirology</i> , 2010, 15, 1017-1018.	1.3	11
310	Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B. <i>Hepatology International</i> , 2013, 7, 119-126.	1.9	11
311	Hepatitis B: treatment choice and monitoring for response and resistance. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 697-707.	1.4	11
312	Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. <i>Clinical Endocrinology</i> , 2021, 95, 478-488.	1.2	11
313	Recombinant interferon- β in inoperable hepatocellular carcinoma: A randomized controlled trial. <i>Hepatology</i> , 1993, 17, 389-394.	3.6	11
314	Role of cholecystectomy in preventing recurrent cholangitis. <i>Gastrointestinal Endoscopy</i> , 2002, 56, 55-60.	0.5	10
315	Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection. <i>Current Hepatitis Reports</i> , 2011, 10, 106-111.	0.3	10
316	Effect of Hepatitis B Virus Reverse Transcriptase Variations on Entecavir Treatment Response. <i>Journal of Infectious Diseases</i> , 2014, 210, 701-707.	1.9	10
317	Hepatitis B virus full-length genomic mutations and quasispecies in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 1638-1645.	1.4	10
318	Reversal of Protein-Losing Enteropathy by Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 86-87.	1.1	10
319	Stanniocalcin 1 is a serum biomarker and potential therapeutic target for HBV-associated liver fibrosis. <i>Journal of Pathology</i> , 2022, , .	2.1	10
320	Hepatitis D virus superinfection remains a rare occurrence in non-drug abusers in Hong Kong. <i>Journal of Hepatology</i> , 1992, 14, 332-334.	1.8	9
321	Current and future antiviral agents for chronic hepatitis B. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 51, 481-485.	1.3	9
322	Telbivudine: an upcoming agent for chronic hepatitis B. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 489-494.	2.0	9
323	Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance. <i>Liver International</i> , 2016, 36, 642-650.	1.9	9
324	Artificial Neural Network Accurately Predicts Hepatitis B Surface Antigen Seroclearance. <i>PLoS ONE</i> , 2014, 9, e99422.	1.1	9

#	ARTICLE	IF	CITATIONS
325	Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy. <i>Antiviral Therapy</i> , 2009, 14, 679-685.	0.6	9
326	Impact of precore and core promoter mutations on hepatic histology in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 301-307.	1.9	8
327	Emerging drugs for the treatment of hepatitis B. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 183-193.	1.0	8
328	An update on the toxicological considerations for protease inhibitors used for hepatitis C infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 483-491.	1.5	8
329	Model for End-Stage Liver Disease With Additional Criteria to Predict Short-Term Mortality in Severe Flares of Chronic Hepatitis B. <i>Hepatology</i> , 2020, 72, 818-828.	3.6	8
330	Significance of viral load, core promoter/precure mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. <i>Antiviral Therapy</i> , 2006, 11, 779-86.	0.6	8
331	Stability of hepatitis B surface antigen over time: Implications for studies using stored sera. <i>Journal of Medical Virology</i> , 2011, 83, 1900-1904.	2.5	7
332	Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1410-1412.	2.4	7
333	Prediction of hepatocellular carcinoma development by aminotransferase to platelet ratio index in primary biliary cholangitis. <i>World Journal of Gastroenterology</i> , 2017, 23, 7863-7874.	1.4	7
334	Prevalence and characteristics of familial hepatocellular carcinoma caused by chronic hepatitis B infection in Hong Kong. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 401-406.	1.9	6
335	Determinants for the Occurrence of Acute Exacerbation of Hepatitis B Virus Infection in Chinese Patients after HBeAg Seroclearance. <i>Journal of Clinical Microbiology</i> , 2005, 43, 1594-1599.	1.8	6
336	Hepatitis B surface antigen levels after hepatitis B antigen seroclearance: a longitudinal follow-up study. <i>Liver International</i> , 2015, 35, 854-859.	1.9	6
337	Oral Nucleos(t)ide Analogs Alone After Liver Transplantation in Chronic Hepatitis B With Preexisting rt204 Mutation. <i>Transplantation</i> , 2017, 101, 2391-2398.	0.5	6
338	A comprehensive HBV array for the detection of HBV mutants and genotype. <i>Clinical Biochemistry</i> , 2011, 44, 1253-1260.	0.8	5
339	Future Prevention and Treatment of Chronic Hepatitis B Infection. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 725-734.	1.1	5
340	Factors for Hepatitis B vaccination and Abnormal Liver Function in Chinese Patients with Inflammatory Bowel Disease: A Single Center Experience. <i>Journal of Digestive Diseases</i> , 2013, 14, n/a-n/a.	0.7	5
341	The role of interleukin-27 in predicting spontaneous HBsAg seroconversion in chronic hepatitis B infection. <i>Liver International</i> , 2017, 37, 1287-1294.	1.9	5
342	HLA-DP and Î³-interferon receptor gene variants and their association with viral hepatitis activity in chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 533-539.	1.4	4

#	ARTICLE	IF	CITATIONS
343	Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 101-106.	1.5	4
344	Deferred treatment with a fixed-dose combination of sofosbuvir and velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1229-1232.	1.0	4
345	Measuring and Validating a General Cancer Predisposition Perception Scale: An Adaptation of the Revised-IPQ-Genetic Predisposition Scale. <i>PLoS ONE</i> , 2015, 10, e0142620.	1.1	4
346	Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. <i>Hepatology</i> , 1995, 22, 25-29.	3.6	3
347	Transarterial chemoembolization for inoperable, early stage hepatocellular carcinoma in patients with Child-Pugh grade A and B results of a comparative study in 96 Chinese patients. <i>American Journal of Gastroenterology</i> , 2003, 98, 1181-1185.	0.2	3
348	Prediction of treatment outcomes for lamivudine. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 964-965.	1.4	3
349	Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B mono-infection. <i>Hepatology International</i> , 2013, 7, 327-334.	1.9	3
350	Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2019, 220, 940-950.	1.9	3
351	L-dT: An ongoing phase I/IIa dose-escalation trial in patients with chronic HBV infection (NV-02B-001). <i>Gastroenterology</i> , 2001, 120, A572.	0.6	2
352	Recombinant Interferon Alfa 2b Therapy in a Patient With Metastatic Hepatocellular Carcinoma. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 272-275.	1.1	2
353	Specific Considerations in the Design of Hepatitis B Virus Clinical Studies in the Far East. , 2004, 96, 457-464.		2
354	Overcoming the problem of chronic hepatitis B. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2006, 3, 197-202.	0.5	2
355	Telbivudine for chronic hepatitis B: the GLOBE trial. <i>Future Virology</i> , 2008, 3, 317-323.	0.9	2
356	The saga of entecavir. <i>Hepatology International</i> , 2009, 3, 421-424.	1.9	2
357	To stop or not to stop: The quest for long-term viral suppression. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 420-422.	1.4	2
358	Management of Chronic Hepatitis B in Patients from Special Populations. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021527-a021527.	2.9	2
359	Serum ceruloplasmin monitoring in a case of silver intoxication due to intravenous silver infusion. <i>Clinical Toxicology</i> , 2022, 60, 255-258.	0.8	2
360	Treatment of Chronic Hepatitis C with Different Genotypes. , 2008, , 130-147.		2

#	ARTICLE	IF	CITATIONS
361	Prevalence and significance of hepatitis GB virus-c/hepatitis G virus viremia in a large cohort of patients with chronic hepatitis B infection, with chronic hepatitis C infection, and on renal replacement therapy in Hong Kong. <i>Digestive Diseases and Sciences</i> , 2002, 47, 432-437.	1.1	1
362	Treatment for Hepatitis B. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, S134-S135.	1.1	1
363	What Is the Best End Point for Hepatitis B Treatment?. <i>Annals of Internal Medicine</i> , 2008, 148, 560.	2.0	1
364	471 HBV DNA Levels Predict Significant Liver Histology for HBeAg-Negative Chronic Hepatitis B Patients. <i>Gastroenterology</i> , 2010, 138, S-788.	0.6	1
365	Reply to Liao et al. <i>Clinical Infectious Diseases</i> , 2013, 57, 622-622.	2.9	1
366	Reply:. <i>Hepatology</i> , 2013, 58, 1857-1857.	3.6	1
367	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	1.1	1
368	Memoir on hepatitis and liver disease history in Hong Kong. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S510-S510.	1.4	0
369	Entecavir. <i>Drugs</i> , 2006, 66, 1623-1624.	4.9	0
370	Recommendations and potential future options in the treatment of hepatitis B. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 2225-2231.	0.9	0
371	Acute Hepatitis as a Presentation of Acute Appendicitis in an Immunocompromised Patient. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, 203-204.	1.1	0
372	Clinical experience and follow-up with lamivudine in the Asian population. , 2003, , 383-390.		0
373	New Antiviral Treatment for Chronic Hepatitis B. , 2004, , 47-56.		0
374	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 34-6.	0.7	0